Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

The claim wasn't that Ebolacide 2 testing was

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Nanotoday Member Profile
 
Followed By 16
Posts 3,906
Boards Moderated 0
Alias Born 06/02/10
160x600 placeholder
NanoViricides reports strong pre-clinical data for COVID-19 drugs Seeking Alpha - 3/9/2021 11:26:50 AM
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....Cont InvestorsHub NewsWire - 3/9/2021 9:30:00 AM
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical InvestorsHub NewsWire - 3/2/2021 7:00:08 AM
NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies Seeking Alpha - 3/2/2021 6:43:58 AM
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....cont InvestorsHub NewsWire - 2/17/2021 7:00:00 AM
NanoViricides reports FQ2 results Seeking Alpha - 2/17/2021 6:28:57 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/16/2021 4:40:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 9:48:43 AM
NanoViricides’s anti-coronavirus candidate was well tolerated in animal studies Seeking Alpha - 2/8/2021 6:46:46 AM
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C... InvestorsHub NewsWire - 2/8/2021 6:36:27 AM
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants InvestorsHub NewsWire - 1/27/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/26/2021 11:05:24 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/4/2021 11:45:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/10/2020 4:31:33 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/3/2020 4:31:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 4:53:44 PM
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA InvestorsHub NewsWire - 11/19/2020 6:47:01 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2020 4:33:46 PM
NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 InvestorsHub NewsWire - 11/11/2020 7:14:53 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/26/2020 4:25:50 PM
Annual Report (10-k) Edgar (US Regulatory) - 10/13/2020 5:23:45 PM
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 InvestorsHub NewsWire - 9/16/2020 7:17:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/3/2020 5:20:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/31/2020 5:30:54 PM
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 InvestorsHub NewsWire - 7/21/2020 9:42:43 AM
Nanotoday   Thursday, 08/27/15 10:36:52 AM
Re: leifsmith post# 114766
Post # of 145298 
The claim wasn't that Ebolacide 2 testing was sure to result in a completely successful test of a viricide against Ebola. The claim was that there was very ilttle risk in doing the testing.

What many (including myself) claimed was that failure of Ebolacide would put the entire platform in question, and make company claims about rapid response and ease of new treatment development suspect.

I believe that is exactly what happened and is certainly part of the decline from the time your trusted associate made the claim until now. From $3 to under a buck.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences